NeuroSense Therapeutics Warrant
NRSNW
3 hedge funds and large institutions have $56.7K invested in NeuroSense Therapeutics Warrant in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
131% more capital invested
Capital invested by funds: $24.6K → $56.7K (+$32.1K)
50% more funds holding
Funds holding: 2 → 3 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$107 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$42 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $36.1K | +$35.7K | +100,402 | New |
|
|
CS
2
Clear Street
New York
| $20.3K | -$107 | -300 | -0.5% |
|
|
3
UBS Group
Zurich,
Switzerland
| $291 | -$42 | -117 | -9% |
|
NRSNW Hedge Fund Activity: Q4 2025 in Review
3 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2025, worth a combined $56.7K — up 131% from $24.6K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest seller was Clear Street, cutting an estimated $107.
- 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2025, up from 2 in Q3 2025.
- Funds reported $56.7K of NeuroSense Therapeutics Warrant stock for Q4 2025, up 131% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q4 2025 and 0 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics Warrant seller in Q4 2025 was Clear Street, an estimated $107 sold.
Based on aggregated 13F filings for Q4 2025.